Research Article

Essential role of MALAT1 in reducing traumatic brain injury

An experiment demonstrated that MALAT1 could promote angiogenesis following traumatic brain injury via the EZH2-NOTCH axis

Graphical Abstract

From the Contents

Introduction 1776
Materials and Methods 1777
Results 1779
Discussion 1782

Abstract

As a highly evolutionary conserved long non-coding RNA, metastasis associated lung adenocarcinoma transcript 1 (MALAT1) was first demonstrated to be related to lung tumor metastasis by promoting angiogenesis. To investigate the role of MALAT1 in traumatic brain injury, we established mouse models of controlled cortical impact and cell models of oxygen-glucose deprivation to mimic traumatic brain injury in vitro and in vivo. The results revealed that MALAT1 silencing in vitro inhibited endothelial cell viability and tube formation but increased migration. In MALAT1-deficient mice, endothelial cell proliferation in the injured cortex, functional vessel density and cerebral blood flow were reduced. Bioinformatic analyses and RNA pull-down assays validated enhancer of zeste homolog 2 (EZH2) as a downstream factor of angiogenesis. Taken together, our results suggest that MALAT1 controls the key processes of angiogenesis following traumatic brain injury in an EZH2/NOTCH1-dependent manner.

Key Words: angiogenesis; controlled cortical impact; EZH2; Jagged-1; LncRNA; MALAT1; NOTCH1; oxygen-glucose deprivation; traumatic brain injury; vascular remodeling

Introduction

Traumatic brain injury (TBI) is associated with high morbidity and mortality worldwide. In the past 150 years, the mortality rate of patients with severe TBI has decreased by more than 50% but remains as high as 30% (Stein et al., 2010). Over 30 clinical trials of patients with severe TBI have been carried out, but the outcomes have been unsuccessful. Consequently, effective treatments for TBI remain limited (Diaz-Arrastia et al., 2014; Wright et al., 2014).

Long non-coding RNAs (LncRNAs) are a novel class of RNA with >200 nucleotides that lack a complete open reading frame. Recently, LncRNAs have been extensively reported to have vital epigenetic regulatory potential (Yao et al., 2019; Di et al., 2021; Liang et al., 2021), but their role in TBI pathology remains unclear. Three independent studies investigated the expression profiles of LncRNA after TBI in the brain tissues of mice, rats and humans (Zhong et al., 2016; Wang et al., 2017; Yang et al., 2017). Several differentially expressed LncRNAs have been identified to date (Tuchscherer et al., 1992). For example, LncRNA Gm4419 promotes astrocytic apoptosis after TBI by upregulating tumor necrosis factor-alpha (Yu et al., 2017a). In addition, LncRNA Neat1 inhibits cell apoptosis and inflammation by capturing p53-induced death domain protein 1 following TBI (Zhong et al., 2017). We previously found that metastasis associated lung adenocarcinoma transcript 1 (MALAT1) is one of the most abundant LncRNAs expressed in brain tissue before and after controlled cortical impact (CCI), whereas the functions of other highly expressed LncRNAs were mostly undefined under RNA sequencing (unpublished data). MALAT1, a highly evolutionarily conserved LncRNA with a length of ~8000 nucleotides, was first reported to be related to the metastasis of lung tumors (Ji et al., 2003). MALAT1 overexpression ameliorates brain edema in TBI by inhibiting the nuclear factor kappa-B/interleukin-6 pathway and aquaporin 4 expression (Zhang et al., 2019). Several studies have shown that MALAT1 regulates angiogenesis (Leisegang et al., 2017; Zhang et al., 2018; Wang et al., 2019). Furthermore, MALAT1

1Department of Neurosurgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China; 2Department of Neurosurgery, Qilu Hospital of Shandong University (Qingdao Campus), Qingdao, Shandong Province, China

*Correspondence to: Han Liu, PhD, 1019266517@qq.com.
https://orcid.org/0000-0001-5726-8751 (Han Liu); https://orcid.org/0000-0001-8806-2422 (Na Wu)

#Both authors contributed equally to this work.

Funding: The study was supported by the National Natural Science Foundation of China, No. 81571159 (to XCS); the National Natural Science Foundation of China (Youth Program), No. 81601072 (to CJC); and the National Natural Science Foundation of Chongqing, China, No. cstc2019jcyj-msxmX0830 (to CJC).

How to cite this article: Wu N, Cheng CJ, Zhong JJ, He JC, Zhang ZS, Wang ZG, Sun XC, Liu H (2022) Essential role of MALAT1 in reducing traumatic brain injury. Neural Regen Res 17(8):1776-1784.
modulates endothelial cell function and blood vessel growth (Michalk et al., 2014), but the role of MALAT1 in the cerebral vasculature after TBI requires further clarification.

During the acute phase of TBI, vascular injury disrupts the blood-brain barrier, resulting in hemorrhage and/or edema expansion. The blood-brain barrier is the microenvironment of the central nervous system that allows for proper neuronal function. The properties of the blood-brain barrier are largely attributed to endothelial cells (Danneman and Prat, 2015). Over time, the angiogenic effect of MALAT1 promotes vascular restoration, including vasculature reconstruction and cerebral blood flow recovery. Therefore, strategies to enhance these effects may provide promising opportunities to improve clinical outcomes for patients with TBI (Salehi et al., 2017). In our study, we aimed to investigate the potential role of MALAT1 in vascular remodeling following TBI and further explore its molecular mechanisms.

Materials and Methods
Animals
Male C57BL/6 mice (n = 223, aged 12 weeks, weight 25–30 g) were purchased from the Experimental Animal Center of Chongqing Medical University (Chongqing, China). All mice were housed in cages with food and water available ad libitum. All experiments were approved by the Chongqing Medical University Administrative Panel on Laboratory Animal Care on September 25, 2017 (approval No. 2017–147). All experiments were designed and reported in accordance with the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines (Percie du Sert et al., 2020). All experiments performed under anesthesia, and mice were anesthetized by inhalation with 3% isoflurane (flow rate 3 L/min, Yuyan Instruments, Shanghai, China) in 67% N2O/30% O2, until they did not respond to a tail pinch. Then, 1.5% isoflurane (flow rate 0.5 L/min) was used for anesthesia maintenance.

Experimental design
The experimental process is shown in Figure 1A. The grouping of animals was random.

Experiment I
To determine the time course of MALAT1 expression, polymerase chain reaction (PCR) analysis was performed 6 hours and 1, 3, 7, 14, 21 and 28 days after TBI insult (n = 4/time point). To determine MALAT1 localization, fluorescence in situ hybridization (FISH) analysis was performed on day 7 following CCI (n = 4/group). For outcome evaluation, mice were divided into sham, sham-siMALAT1, CCI and CCI-siMALAT1 groups (n = 6/group). Neurological severity score (NSS) analyses and wire grip tests were performed in vivo. MALAT1 small interfering RNA (siRNA) or negative control siRNA (si-NC) was injected intraperitoneally on day 1 post-CCI and then injected daily for 7 consecutive days.

Cell culture and OGD
Cerebral microvessels were isolated from the brains of male C57BL/6 mice based on a previously reported method (Yin et al., 2006). Cerebral cortices were dissected and homogenized. After centrifugation (10,000 × g for 5 minutes at 4°C), the precipitates were collected and resuspended in PBS. For outcome evaluation, NSS analyses and wire grip tests were performed in vivo after the inhibition of MALAT1 with an adeno-associated virus (AAV) on day 7 following CCI.

Experiment III
StarBase software (https://starbase.sysu.edu.cn/) was used to predict the function interaction probability between MALAT1 and RNA-binding proteins. According to an online RNA-protein interaction prediction database (http://pridb.gdbạch.iastate.edu/RPSeq/) (Huang et al., 2017), enhancer of zeste homolog 2 (EZH2) exhibited high affinity for MALAT1 (random forest [RF] = 0.95 and support vector machine [SVM] scores = 0.76). First, we found the nucleic acid sequence of EZH2 in mouse brain. Then, nucleotide sequences of MALAT1 were recorded. Second, the sequence was entered into StarBase software. The MALAT1–EZH2–NOTCH1 axis was evaluated in vitro by western blot 24 hours following oxygen-glucose deprivation (OGD).

Experiment IV
To investigate the mechanism of angiogenesis, cell proliferation, migration and tube formation assays were performed in vitro in the presence of Jagged-1 combined with MALAT1 downregulation 24 hours after OGD. Under the same conditions, immunohistochemical staining of CD31/BrdU and lectin and cerebral blood flow monitoring were performed on day 7 following CCI. The mice were divided into CCI, CCI-siMALAT1 and CCI-siMALAT1 + Jagged-1 groups (n = 5/group).

Experiment V
For outcome evaluation, NSS analyses and wire grip tests were performed in vivo in the presence of Jagged-1 combined with MALAT1 downregulation. The mice were divided into CCI, CCI-siMALAT1 and CCI-siMALAT1 + Jagged-1 groups (n = 6/group).

Experiment VI
The effect of MALAT1 on angiogenesis was confirmed by locked nucleic acid (LNA) GapmER (MALAT1 inhibitor) in vivo (on day 7 following CCI) and in vitro (24 hours following OGD). Mice were divided into CCI and CCI-GapmER groups (n = 5/group).

CCI
According to previous studies (Jiang and Brody, 2012; Zhong et al., 2017; Zhou et al., 2020), CCI was produced to produce a moderately severe contusion in the right sensorimotor cortex and underlying hippocampus, with pronounced behavioral deficits but virtually no mortality. The impact parameters were set as follows: 5.0-m-second velocity, 100-ms dwelling time, 2.0-mm depth and 3.0-mm diameter impactor (Zhong et al., 2017; Zhou et al., 2020). Sham mice underwent craniotomy without CCI. Mice maintained normal body temperature throughout the entire procedure. Brdu (50 mg/kg; MilliporeSigma, Billerica, MA, USA) was first injected intraperitoneally on day 1 post-CCI and then injected daily for 7 consecutive days.

AAV administration
AAV-mALAT1 (GenePharma, Shanghai, China) was used to knock down MALAT1, and AAV-green fluorescent protein (AAV-GFP) was used as a control (Genechem, Shanghai, China). The MALAT1 siRNA sequence was 5′-GCA GTT TAG AGT CTT TAG-3′, and the control sequence was 5′-TTC TCC GCC GCA GTG ACG T-3′. Both AAVs were diluted to 1 × 10⁶ transducing units (TU)/ml in enhanced transfection solution (Genechem) before use. The intracerebroventricular injection procedure was performed in accordance with previous studies (Zhu et al., 2005; Zhou et al., 2020). Five microliters of diluted AAV-mALAT1 or AAV-GFP were slowly injected into the lateral ventricle on day 14 before TBI. CCI mice were injected with phosphate buffered saline (PBS).

Lentiviral transfection of endothelial cells
A lentivirus was prepared (GenePharma) to decrease the RNA level of MALAT1. Lentiviral transfection of endothelial cells with the lentivirus, the virus infection, was also added into the culture media.
Endothelial cells (1 × 10⁴ cells/well) were seeded in a 96-well plate, and the number of viable cells was determined using Cell Counting Kit-8 (Dojindo Molecular Technologies, Gaithersburg, MD, USA) following the manufacturer’s suggestions. Each well received 10 μL Cell Counting Kit-8. The number of living cells was assessed by measuring the absorbance at 450 nm at 24 hours. Cell viability (%) was calculated as follows: experimental group absorbance value/control group absorbance value × 100. The sham group is the control group absorbance value × 100. The sham group is the control group absorbance value × 100.

RNA-FISH
RNA-FISH was carried out based on the manufacturer’s suggestions and a previous study (Wan et al., 2019). Briefly, mice were perfused with 4% formaldehyde in phosphate buffer (pH 7.2). Brains were dissected, post-fixed for 2 hours at 4°C in the same fixative, and then cryoprotected at 4°C in 20% sucrose in phosphate buffer (pH 7.2). Coronal and sagittal sections (10 μm thick) were made using a cryotome. Fluorescent FISH probe mixes were ordered from commercial sources (RIBOBIO, Guangzhou, China). To achieve a sufficient signal-to-background ratio, multiple probes were targeted along each LncRNA sequence. A set of 15–220 probes covering the entire length of the RNA molecule provided an optimal signal strength, and each probe carried multiple fluorophores. The pooled FISH probes were resuspended to a final concentration of 25 μM in RNase-free storage buffer and protected from light at −20°C.

The endothelium was labeled by von Willebrand factor (1:200, Cat# 28129-1-AP, RRID:AB_2280791, Proteintech, Chicago, IL, USA), and the cell nucleus was labeled by 4,6-diamidino-2-phenylindol (MilliporeSigma).

NSS and wire grip test
NSS analyses and wire grip tests were performed in accordance with previous research (Flierl et al., 2009; Wang et al., 2013; Zhong et al., 2017; Zhou et al., 2020). Briefly, the NSS measured general behavior, alertness, balance and motor ability, including ten different tasks. One point was obtained for each failed task. Zero points represented the minimum deficit, and ten points represented the maximum deficit. Wire grip tests were used to evaluate three-dimensional motor function. The apparatus consisted of a stainless-steel bar (50-cm length; 2-mm diameter) mounted on two vertical supports and was observed for 60 seconds. A five-point scale was used. Zero points represented the maximum deficit, and five points represented the minimum deficit. Mice were evaluated on the pre-injury day and days 1, 3, 7, 14, 21 and 28 after CCI.

Construction of pcEZ2 overexpression plasmid
To verify the downstream effect of EZH2, the recombinant plasmid pcDNA3.1(+)–EZH2 overexpressing EZH2 was constructed (termed pcEZ2). The DNA MiniPrep or MidiPrep Kit (QIAGEN, Düsseldorf, Germany) was used to prepare plasmid vectors (pcDNA3.1(+)–EZH2 and empty vector pcDNA3.1-GFP) for cell transfection (endothelial cells cultured in a six-well plate) via Lipofectamine 2000 (Invitrogen). FISH was performed using the manufacturer’s instructions. The overexpression efficiency was detected by western blot analysis or real-time qRT-PCR 48 hours after transfection.

LNA GapmR transfection in vitro and in vivo
Endothelial cells were transfected at 60–75% confluence with 100 nM synthesized siRNAs (MilliporeSigma) or 1–100 nM LNA GapmRs (Exiqon, Vedbaek, Denmark) targeting MALAT1 using Lipofectamine RNAiMax (Life Technologies, Carlsbad, CA, USA) in accordance with the manufacturer’s protocol. As controls, scrambled LNA GapmRs or siFirefly luciferase was transfected. Four hours after transfection, the medium was replaced by EBM (Lonza, Basel, Switzerland) supplemented with EGM-SingleQuots (Lonza) and 10% fetal calf serum (Invitrogen).

LNA GapmRs were dissolved and diluted in nuclease-free, sterile water in accordance with the manufacturer’s protocol. LNA GapmR MALAT1 (20 mg/kg; Exiqon) or LNA GapmR Ctrl (20 mg/kg; Exiqon) was injected intravenously pre- and post-surgery as described (Michaïl et al., 2014).

Cell viability assay
Endothelial cells (1 × 10⁴ cells/well) were seeded in a six-well plate. The plates were coated with human fibronectin (1 μg/mL, MilliporeSigma) overnight at room temperature. Then, cells were detached with trypsin after 24 hours and incubated overnight in 5% CO₂ at 37°C. The next day, the cell monolayer was rinsed once with PBS. Micrographs of wounds were obtained at 0 and 24 hours using a Zeiss Observer 21 microscope (Leica, Wetzlar, Germany). Image V1.8.0 software (National Institutes of Health, Bethesda, MD, USA) was used to assess the mean migration distance.

Tube formation assay
The tube formation of endothelial cells was assessed using an in vitro Angiogenesis Assay Kit (Chemicon, Temeucula, CA, USA). Endothelial cells were seeded at 5 × 10⁴ cells/cm². After 2 hours, the conditioned medium was harvested and filtered via a 0.2-μm filter (Sartorius Stedim Biotech, Göttingen, Germany). Endothelial cells were cultured in a CO₂ incubator for 24 hours at 37°C. Cultures were photographed (40× magnification), and the number of tubes was calculated.

Endothelial cell proliferation in vivo
Brain sections (10 μm) were fixed in 4% paraformaldehyde, then blocked with 5% fetal bovine serum for 80 minutes. The slices were incubated overnight at 4°C with mouse monoclonal anti-CD31 (1:100, Cat# ab224590, RRID:AB_448167, Abcam, Cambridge, UK) and rat antibody polyclonal anti-Brdu (1:200, Cat# ab152095, RRID: AB_2813902, Abcam). Slides were washed and incubated at room temperature for 2 hours with the appropriate secondary antibodies, including DyLight 594 goat anti-mouse IgG (1:200, Cat# ab96898, RRID: AB_10680252, Abcam) and DyLight 488 goat anti-rabbit IgG (1:200; Cat# ab96899, RRID: AB_10679361, Abcam). Slices were analyzed using a fluorescence microscope (Leica). Angiogenesis was evaluated by calculating the number of CD31/Brdu double-positive cells in peri-lesion areas of ipsilateral hemispheres (cortex and subcortex).

Quantification of blood vessel density
Briefly, lectin dye (0.2 mg/mL, Vector Laboratories, Burlingam, CA, USA) in a volume of 300 μL was given via tail vein injection and allowed to circulate for 10 minutes before sacrifice. Brains were examined under a fluorescence microscope. Functional vessel density was evaluated by the area ratio of lectin-positive blood vessels in the cortex and subcortex surrounding the injury site.

Two-dimensional laser speckle imaging techniques
Cerebral blood flow is defined as the amount of arterial blood per unit mass delivered to brain tissue per unit time and is a sensitive physiological index reflecting cerebrovascular function (Joris et al., 2018). Cerebral blood flow was monitored using laser speckle techniques (PeriCam PSI System; Perimed, Stockholm, Sweden) following previous reports (Li et al., 2013; Liao et al., 2017; Liu et al., 2018). Briefly, the camera head was adjusted to ensure that the red cross-point of the indicator laser (660 nm) was located at the center of the brain, and the measurement distance was set at 10 cm. The size of the test area was adjusted with PIM Software version 1.5 (PeriCam PSI System). Cerebral blood flow signals were collected at 785 nm and transferred into blood perfusion images using PIM Software. Perfusion images were acquired using a PeriCam high resolution LSCI system (PeriCam PSI System) with a 70-mW built-in laser diode for illumination and a CCD camera (PeriCam PSI System) on days 1, 3, 7, 10, 14, 21 and 28 post-TBI. The scanner was positioned to scan a 1.5 cm × 1.5 cm area (1600 detection points), covering the cross-point of the coronal and sagittal sutures. A built-in photo detector equipped with LDPI Win software (PeriCam PSI System) was used to detect the reflected light from moving blood.
cells within a depth of 0.5 cm from the cortical surface. Color-coded images were acquired three times continuously, and the average cerebral blood flow was calculated based on the concentration and mean velocity of the blood cells using LDPI Win software. The cerebral blood flow for the ipsilateral side was calculated as a percent of the corresponding contralateral side.

**Western blot analysis**

Western blot analysis was performed as previously described (Huang et al., 2016; Zhou et al., 2020). Briefly, endothelial cells were collected for total protein extraction. The sample proteins (20 μg per lane) were separated in 12% bisacrylamide gels (Invitrogen) and transferred onto polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). Membranes were blocked with 5% non-fat milk for 1 hour at room temperature, then incubated overnight at 4°C with primary antibodies, including rabbit monoclonal anti-β-actin (1:5000, Cat# ab212362, Abcam), rabbit polyclonal anti-β-actin (1:5000, Cat# 20536-1-AP RRID:AB_1000003, Proteintech), rabbit polyclonal anti-EZH2 (1:1000, Cat# 5246, RRID:AB_10694683, Cell Signaling Technology, Danvers, MA, USA); rabbit monoclonal anti-hairy and enhancer of split 1 (HES1;1:1000, Cat# ab108937, RRID:AB_10862625, Abcam) and rabbit monoclonal anti-Notch1 (1:1000, Cat# ab52627, RRID:AB_881725, Abcam). After being washed with Tris-buffered saline/Tween-20, membranes were incubated for 1 hour at room temperature with horseradish peroxidase-conjugated AffiniPure goat anti-rabbit IgG (1:5000; Cat# SA00001-2, RRID:AB_2722564, Proteintech). Enhanced chemiluminescence was used to detect proteins in the membranes (ECL Plus, Amersham Biosciences, Little Chalfont, UK). The biotinylated RNAs were incubated at room temperature. Finally, the eluted proteins were analyzed by western blot analysis.

**RNA pull-down**

RNA pull-down was performed as previously described (Huang et al., 2017). Briefly, MALAT1 transcripts were transcribed using T7 RNA polymerase (Ambion Life Technologies) in vitro. RNA was purified with the RNeasy Plus Mini Kit (Qiagen), then treated with DNase I (Qiagen). Purified RNAs were labeled with Biotin RNA Labeling Kit (Roche Diagnostics, Indianapolis, IN, USA). The biotinylated RNAs were mixed and incubated with endothelial cell lysates. Then, magnetic beads were added to each binding reaction, and the mixtures were incubated at room temperature. Finally, the eluted proteins were identified through western blot analysis.

**Statistical analysis**

No statistical methods were used to determine sample sizes; however, sample sizes are similar to those reported in previous publications (Ji et al., 2003; Jäe and Dimmeler, 2015). No animals or data points were excluded from the analysis. All quantitative data are shown as the mean ± standard error of the mean (SEM). The neurological behavioral data were analyzed using two-way repeated-measures analysis of variance (Dhabagh-Gossart et al., 2016), followed by Tukey’s post hoc test across groups. The qRT-PCR data of MALAT1 and EZH2 in vivo were analyzed by one-way analysis of variance, followed by Dunnett’s post hoc test. Other data tested in three or four experimental groups were analyzed by one-way analysis of variance, followed by Tukey’s post hoc test. Data tested in only two groups were analyzed by Student’s t-test. All data were analyzed using Graphpad Prism 7.0 software (GraphPad Software, San Diego, CA, USA). The level of statistical significance was set at P < 0.05.

**Results**

**MALAT1 expression profile following TBI**

In our previous study (Zhong et al., 2016), global lncRNA expression was evaluated before and after CCI, and MALAT1 was one of the highly expressed lncRNAs. Here, we found that the MALAT1 level in the injured cortex rapidly increased as early as 6 hours after CCI (P < 0.001), then gradually decreased to the lowest level at 7 days after CCI (P < 0.001; Figure 1B). The MALAT1 level was increased in cultured endothelial cells at 24 hours after OGD (P < 0.05; Figure 1C). RNA-FISH analysis showed that MALAT1 immunoreactive cells were located in the cortical endothelium in model mice (Figure 1D).

**MALAT1 deficiency aggravates neurobehavioral deficits after CCI**

To determine the effects of MALAT1 on functional outcomes after CCI, we compared the NSS and wire grip test results (Figure 1E and F). After CCI, significant neurological impairments were observed in the CCI group compared with the sham group (P < 0.05; Figure 1E and F). Based on the NSS, CCI-siMALAT1 animals developed more severe sensorimotor deficits compared with the CCI group (P < 0.05; Figure 1E). In the wire grip test, the CCI-siMALAT1 group exhibited deteriorated motor performance compared with the CCI group (P < 0.05, Figure 1F).

**MALAT1 downregulation disrupts angiogenesis following TBI**

Here, we explored the potential effects of MALAT1 on cerebral angiogenesis. We found that endothelial proliferation and functional vessel density were affected after OGD and CCI (P < 0.05; Figure 2A–F). Endothelial cell viability (P < 0.05; Figure 2A) and tube formation (P < 0.05; Figure 2B) were decreased in the sham-siMALAT1 group compared with the sham group. MALAT1 inhibition suppressed endothelial proliferation and tube formation but promoted endothelial migration (P < 0.05; OGD-siMALAT1 group vs. OGD group; Figure 2C). Furthermore, we found that MALAT1 enhanced endothelial proliferation (day 7), functional vessel density (day 21) and cerebral perfusion (day 7) in the lesion areas following CCI (P < 0.05, CCI-siMALAT1 group vs. CCI group; Figure 2D–F).

**EZH2 and NOTCH1 act downstream of MALAT1 in TBI neuropathologies**

EZH2 exhibited a high affinity for MALAT1 (RF = 0.95 and SVM = 0.76). This binding probability was further supported by StarBase (Figure 3A). As a key regulator of tumor angiogenesis, EZH2 is predominantly upregulated in cancer-derived endothelium, promoting endothelial tube formation (Crea et al., 2012). To investigate the potential interaction between MALAT1 and EZH2, an RNA pull-down assay was performed to evaluate their binding in endothelial cells. The results confirmed the association between EZH2 and MALAT1 (P < 0.05; RNA-S vs. RNA-AS; Figure 3B). EZH2 expression was markedly suppressed by siMALAT1, indicating the presence of crosstalk between EZH2 and MALAT1. Following CCI, the transcriptional level of EZH2 increased as early as 6 hours and then gradually decreased to low levels at 7 days compared with the sham group. The decreased levels were maintained in the late phase (P < 0.05; Figure 3C).

Previous studies reported the involvement of NOTCH1 in vascular events. For instance, the miR-32-3p/NOTCH1 axis was found to promote angiogenesis in chronic compressive spinal cord injury (Cheng et al., 2020). Following cerebral ischemia, upregulated NOTCH1 signaling was observed, and NOTCH1 deficiency inhibited local angiogenic activity (Ren et al., 2018). Recently, EZH2 was reported to directly bind to the NOTCH1 promoter and induce its transcription (Gonzalez et al., 2014). Thus, we proposed a hypothesis that the NOTCH1 pathway is involved in MALAT1-EZH2 regulation. EZH2, NOTCH1 and HES1 expression levels were detected by western blot after MALAT1 downregulation in cultured endothelial cells. Our results showed that NOTCH1/HES1 and EZH2 expression were upregulated in the OGD-siMALAT1 group compared with the OGD group (P < 0.05; Figure 3D). The NOTCH1 pathway was suppressed by the EZH2 inhibitor (P < 0.05; OGD-GSK126 group vs. OGD group; Figure 3E), but these effects were reversed by pcEZH2 (P < 0.05, OGD-siMALAT1 vs. OGD-siMALAT1 + pcEZH2 group; Figure 3F).

**NOTCH1 is required in MALAT1-mediated angiogenesis and functional recovery**

To investigate the role of the NOCTH1 pathway in vascular regulation, we tested the angiogenic events following TBI based on previously reported methods (Williams et al., 2006; Britsch et al., 2010). As shown in Figure 4, the effects of MALAT1 on endothelial proliferation, migration and tube formation after OGD were reversed by activation of the NOCTH1 signaling pathway (jagged-1) (P < 0.05; OGD-siMALAT1 + Jagged-1 group vs. OGD-siMALAT1 group; Figure 4A–C). Endothelial proliferation (day 7), functional vessel density (day 21) and cortical perfusion (day 7) surrounding lesion areas following CCI were enhanced by Jagged-1 even in the absence of MALAT1 (P < 0.05; CCI-siMALAT1 + Jagged-1 group vs. CCI-siMALAT1 group; Figure 4D–F). Furthermore, Jagged-1 rescued the effects of MALAT1 on sensorimotor performances (NSS and wire grip test) (P < 0.05; CCI-siMALAT1 + Jagged-1 group vs. CCI-siMALAT1 group; Figure 5A and B).

To validate our results, we performed the above experiments in the presence of the MALAT1 inhibitor LNA GapmeR (Michalk et al., 2014). Consistent with our preliminary findings, GapmeR suppressed angiogenic tube formation and endothelial proliferation and promoted endothelial migration in vitro (P < 0.05; OGD-GapmeR group vs. OGD group; Figure 6A–C). Similarly, GapmeR inhibited endothelial proliferation (d7) and functional vessel density (d21) following CCI (P < 0.05; CCI-GapmeR group vs. CCI group; Figure 6D and E).
MALAT1 expression profile and the effects of MALAT1 on neurological function.

(A) Experimental design in vivo (A1) and in vitro (A2). (B) MALAT1 mRNA expression in brain tissue was detected by qRT-PCR at 6 hours and 1, 3, 7, 14, 21, and 28 days after CCI. The MALAT1 mRNA level rapidly increased as early as 6 hours after CCI, then gradually decreased to the lowest level at 7 days after CCI. (C) MALAT1 mRNA expression was detected at 24 hours after OGD by qRT-PCR. The MALAT1 level was increased in the OGD group compared with the sham group. (D) In situ hybridization detection of MALAT1 in vivo. MALAT1 (red, DyLight 594) co-localized with vWF (green, DyLight 488). Scale bars: 25 μm in D1–3, and 10 μm in D4–6. (E) The NSS. Zero points represented the minimum deficit, and ten points represented the maximum deficit. Data are shown as the mean ± SEM (μm in D4–6. (F) The wire grip tests. Zero points represented the minimum deficit, and five points represented the maximum deficit. Data are shown as the mean ± SEM (μm in D4–6.

Figure 1

Effects of siRNA-mediated MALAT1 silencing on angiogenesis in vitro and in vivo.

Cell viability (by Cell Counting Kit-8) (A), tube formation assay (B) and scratch wound assay (C) after OGD. (D–F) Effects of siMALAT1 on angiogenesis following CCI. The inhibition of MALAT1 suppressed endothelial proliferation and tube formation but promoted endothelial migration. (D) Double immunohistochemical staining of BrdU (green, DyLight 488, a marker of cell proliferation)/CD31 (red, DyLight 594, localized to positive endothelial cells) at 7 days following CCI. The number of BrdU/CD31 double-positive cells was significantly lower in the CCI-siM group compared with the CCI group. Arrows indicate the BrdU/CD31 double-positive cells. (E) Functional vessel density was identified by the staining of perfused lectin at 21 days following CCI. Functional vessel density was significantly lower in the CCI-siM group compared with the CCI group. Circles indicate the CBF in lesion areas. Data are expressed as the mean ± SEM (n = 6/group in A–C, n = 5/group in D–F). *P < 0.05 (one-way analysis of variance followed by Tukey’s post hoc test). BrdU: Bromodeoxyuridine; CBF: cerebral blood flow; CCI: controlled cortical impact; MALAT1: metastasis associated lung adenocarcinoma transcript 1; OGD: oxygen-glucose deprivation; siM: small interfering RNA-metastasis associated lung adenocarcinoma transcript 1.
siMALAT1 suppresses the NOTCH1 signaling pathway through EZH2 downregulation in vitro. (A) Bioinformatics prediction of MALAT1 and EZH2 interaction by StarBase. Left: Several candidate proteins potentially binding to MALAT1 listed in the StarBase system. Right: MALAT1 showed a high affinity to EZH2 in the RNA-protein interaction prediction system (random forest \(RF = 0.95\) and support vector machine SVM scores = 0.76). (B) RNA pull-down assays confirmed the association between EZH2 and MALAT1. EZH2 was detected by western blot in collected samples pulled down by MALAT1. (C) EZH2 mRNA expression profile was detected by qRT-PCR following CCI at 6 hours and 1, 3, 7, 14, 21 and 28 days after CCI. (D) EZH2, NOTCH1 and HES1 expression levels were detected by western blot after MALAT1 downregulation in cultured endothelial cells. The expression levels of NOTCH1, HES1 and EZH2 were suppressed in the OGD-siM group compared with the OGD group. (E) Western blot was applied to test whether the NOTCH1 signaling pathway was regulated by an EZH2 inhibitor (GSK126) in cultured endothelial cells. (F) NOTCH1 and HES1 protein expression levels were detected by western blot after MALAT1 downregulation in cultured endothelial cells. The expression levels of NOTCH1 and HES1 were significantly higher in the CCI-siM + Jagged-1 group compared with the CCI-siM group.

MALAT1 regulates angiogenesis through the NOTCH1 signaling pathway in vitro and in vivo. Cell viability (by Cell Counting Kit-8) (A), tube formation assay (B) and scratch wound assay (C) after OGD. The effects of MALAT1 on endothelial proliferation, migration and tube formation after OGD stimuli were reversed by Jagged-1. (D) Double immunohistochemical staining of BrdU (green, DyLight 488, a marker of cell proliferation)/CD31 (red, Alexa Fluor 546, a marker of endothelial cells) at 7 days following CCI. The number of BrdU/CD31 double-positive cells was significantly higher in the CCI-siM + Jagged-1 group compared with the CCI-siM group. Arrows indicate the BrdU/CD31 double-positive cell. (E) Functional vessel density was identified by the staining of perfused lectin at 21 days following CCI. Functional vessel density was significantly higher in the CCI-siM + Jagged-1 group compared with the CCI-siM group. Scale bars: 50 μm in B, 200 μm in C, 25 μm in D and 12.5 μm in E. (F) Effect of siMALAT1 combined with Jagged-1 on perfusion efficiency in injured sites 7 days following CCI. Two-dimensional laser speckle images of CBF changes (% CBF relative to contralateral hemisphere) in different groups following CCI. CBF was significantly higher in the CCI-siM + Jagged-1 group compared with the CCI-siM group. Circles indicate CBF in the lesion area. Data are shown as the mean ± SEM (\(n = 4/group\) in A–C, \(n = 5/group\) in D–F). *\(P < 0.05\) (one-way analysis of variance followed by Tukey’s post hoc test in C, one-way analysis of variance followed by Tukey’s post hoc test in f, and Student’s t-test in B, D–E). CCI: Controlled cortical impact; EZH2: enhancer of zeste homolog 2; HES1: hairy and enhancer of split 1; MALAT1: metastasis associated lung adenocarcinoma transcript 1; OGD: oxygen-glucose deprivation; qRT-PCR: quantative reverse transcription polymerase chain reaction; siM: small interfering RNA-metastasis associated lung adenocarcinoma transcript 1.
Here, we established a TBI model in experimental mice and cultured cells and performed serial experiments to explore the role of MALAT1 in TBI pathologies. Our data showed that MALAT1 expression was altered in the injured brain hemisphere following CCI and cultured endothelial cells following OGD. MALAT1 downregulation using siRNA and a MALAT1 inhibitor (LNA GapmR) was associated with decreased angiogenic activities, vasculature growth and cerebrovascular perfusion. Mechanistically, we found that MALAT1 promotes angiogenesis by regulating NOTCH1 after binding to EZH2. For technical reasons, a MALAT1 overexpression AAV could not be constructed. Therefore, this study only verified the hypothesis by inhibiting MALAT1. The effect of MALAT1 on other differentiation pathways of neural stem cells was not discussed.

Several studies have demonstrated that enhanced angiogenesis plays a crucial role in secondary brain injury after TBI (Sköld et al., 2005; Mueller et al., 2007; Chen et al., 2013). As reported in the literature (Ren et al., 2019; Aki et al., 2021), functional angiogenesis, pathological angiogenesis, and de novo arteriogenesis refer to the growth of new capillaries. Arterial blood vessels in the brain might be critical for repairing brain injury after TBI. Therefore, strategies based on enhancing angiogenesis might provide therapeutic potential for TBI. lncRNAs have emerged as key regulators of diverse cellular processes (Sun and Kraus, 2015), including those closely associated with angiogenesis (Thum and Fiedler, 2014; Fiedler et al., 2015; Jäe and Dimmel, 2015; Beermann et al., 2016; van Kruisjijk et al., 2016). Recent evidence indicated that lncRNA MALAT1 played an important role in regulating angiogenesis in tumors (Tee et al., 2016) and peripheral vessels (Michalk et al., 2014). MALAT1 was also reported to increase resistance to apoptosis and inflammation induced by experimental ischemic stroke (Zhang et al., 2017). Similarly, we found that MALAT1 enhanced endothelial cell proliferation and tube formation in vitro. The in vivo results further confirmed that MALAT1 promoted endothelial proliferation, vasculature reconstruction and cerebral perfusion recovery after CCI.

We predicted a series of MALAT1 downstream effectors using bioinformatics software. Among these candidates, EZH2 was selected for subsequent experiments for two reasons: 1) EZH2 has a high affinity for MALAT1 and 2) EZH2 was previously reported to regulate vascular function (Crea et al., 2012). As expected, RNA pull-down assays indicated the direct binding of MALAT1 and EZH2 in vitro, which was consistent with previous results (Tee et al., 2016; Kim et al., 2017; Yu et al., 2017b; Wang et al., 2018; Hu et al., 2019). The signaling activated by MALAT1/EZH2 interactions was closely dependent on EZH2 function. EZH2, a catalytic subunit of polycomb repressive complex 2, silences gene transcription via the trimethylation of histone H3 on lysine 27 (H3K27me3). Previous reports indicated that MALAT1 recruits polycomb repressive complex 2 to the promoter region of target genes to enhance H3K27me3 activity, thereby epigenetically inhibiting gene transcription, mainly in cancer and sepsis (Wang et al., 2015; Huo et al., 2017; Lin et al., 2019; Yong et al., 2020). However, in human immunodeficiency virus type 1 (HIV-1)-infected CD4+ T cells, MALAT1 inhibited EZH2 from binding to the HIV-1 long terminal repeat promoter, thereby preventing polycomb repressive complex 2-mediated H3K27me3 and alleviating the epigenetic silencing of HIV-1 transcription (Qiu et al., 2019). More intriguingly, recent evidence showed that EZH2 also potentiates transcriptional activation (Lee et al., 2011; Xu et al., 2012; Asangani et al., 2013), likely independent of its catalytic H3K27me3 activity. One study found that the amino-terminal H1 domain of EZH2 mediated binding to the NOTCH1 promoter and induced its epigenetic activation in breast stem cells (Gonzalez et al., 2014). Similarly, NOTCH1 signaling was suppressed by an EZH2 inhibitor in cultured endothelial cells in our study. It is well documented that the NOTCH1 signaling pathway is a key regulator of tumor angiogenesis via crossstalk with the VEGF/VEGFR system (Kangsmakson et al., 2015). However, whether MALAT1 influences the expression or activity of EZH2 remains unclear. Our study revealed that MALAT1 enhanced the expression of EZH2 and NOCH1, and EZH2 rescued the effects of MALAT1 on NOTCH1. Thus, NOTCH1 is regulated by MALAT1, likely through EZH2. NOTCH1 activation reversed the MALAT1 deficiency-mediated impairment of angiogenesis. These findings suggest that the biological action of MALAT1 involves NOTCH1 signaling.

Experimental animal articles revealed that new vessel sprouts and increased capillary density are detected at a relatively short time after brain injury (Park et al., 2009; Hayward et al., 2011; Salehi et
al., 2017). Sprouting angiogenesis may promote neurologic recovery after TBI (Li et al., 2012). Clinical studies also reported that there was a tendency to increase both the number of blood vessels and blood vessels area fraction after brain injury, which may benefit the clinical outcome following TBI (Li et al., 2016; Kobek et al., 2018). In our study, we investigated the potential role of MALAT1 in brain tissue, which showed the highest expression among LncRNAs. Regarding endothelial function, our results demonstrate that MALAT1 promoted angiogenesis via the EZH2-NOTCH1 axis, which may benefit neurological function recovery following TBI. However, due to the species differences between mice and humans, pre-clinical trials are required to perform before it is applied to the clinic.

Acknowledgments: We express special gratitude to the Chongqing Key Laboratory of Neurology for providing the experimental platform. We thank Professor Yan Wang (Chongqing Medical University, China) for proofreading this paper.

Author contributions: Study conception and design, and manuscript drafting: NW, CJC, HL; data collection: JZJ, JCH, ZSZ; data analysis and interpretation: ZGW; manuscript revision: NW, CJC, HL, XCS. All authors read and approved the final manuscript.

Conflicts of interest: The authors declare that there are no conflicts of interest associated with this manuscript.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons AttributionNon-Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

©Article author(s) (unless otherwise stated in the text of the article) 2022. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

References

Akil A, Gutiérrez-García AK, Guenter R, Rose JB, Beck AW, Chen H, Ren B (2021) Notch signaling in vascular endothelial cells, angiogenesis, and tumor progression: an update and prospective. Front Cell Dev Biol 9:624352.

Asangani IA, Ateeq B, Cao Q, Dodson L, Pandhi M, Kunju LP, Mehra R, Lonigro RJ, Akil A, Gutiérrez-García AK, Guenter R, Rose JB, Beck AW, Chen H, Ren B (2021) MALAT1 predicts poor survival in osteosarcoma patients and promotes cell metastasis through associating with EZH2. Oncarget 8:46993-47006.

Jae N, Dimmeler S (2015) Long noncoding RNAs in diabetic retinopathy. Circ Res 116:1104-1106.

Ji P, Diederichs S, Wang W, Böing S, Metzger R, Schneider PM, Tidow N, Brandt B, Buerger H, Bulk E, Thomas M, Berdel WE, Serve H, Müller-Tidow C (2003) MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22:8031-8041.

Jiang Y, Brody DL (2012) Administration of CGS11410 reduces anoxia-induced precursor protein immunoreactivity and microglial activation after controlled cortical impact in mice. J Neurotrauma 29:2332-2341.

Joris PJ, Mensink RP, AD, Liu TT (2018) Cerebral blood flow measurements in adults: a review on the effects of dietary factors and exercise. Nutrients 10:530.

Kangsamaksin T, Tattersall IW, Kitajewski J (2014) Notch functions in developmental and tumour angiogenesis by diverse mechanisms. Biochem Soc Trans 42:1563-1568.

Kim SH, Kim SH, Yang WI, Kim SJ, Yoon SO (2017) Association of the long non-coding RNA MALAT1 with the polycomb repressive complex pathway in T and NK cell lymphoma. Oncotarget 8:31305-31317.

Kobek M, Jankowski Z, Szala J, Gąszczyk-Ożarowski Z, Palaś A, Skowronek R (2018) Time-related morphometric studies on CD34 protein expression in the cerebral blood vessels after fatal brain contusions. Folia Neuropathol 116:187-195.

Lee JB, Werbowetski-Ogilvie TE, Lee JH, McIntyre BA, Schnerch A, Hong SH, Park IH, Daley GQ, Bernstein ID, Bhatia M (2013) Notch-HES1 signaling axis controls hematopoietic fate decisions of human embryonic and induced pluripotent stem cells. Blood 122:1162-1173.

Lee ST, Li Z, Wu Z, Aas M, Guan P, Karuturi RK, Liu YC, Tu YQ (2012) Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. Mol Cell 43:798-810.

Leisegang MS, Fork C, Josipovic I, Richter FM, Preussner J, Hu J, Miller MJ, Epah J, Fischer A (2010) Integrin cytoplasmic domain-associated protein-1 attenuates sprouting angiogenesis. Circ Res 107:592-601.

Li M, Jia Q, Chen T, Zhao Z, Chen J, Zhang J (2016) The role of vascular endothelial growth factor (VEGF) and VEGF receptor-2 in cerebral angiogenesis after traumatic brain injury: state of the science and the road forward: report of the Department of Defense Neutrauma Pharmacology Workgroup. J Neurotrauma 33:125-158.

Fiedler J, Breckwoldt K, Remmele CW, Hartmann D, Dittrich M, Pfanne A, Just A, Xiao K, Kunz M, Müller T, Hansen A, Geffers R, Dandekar T, Eschenhagen T, Thum T (2015) Development of long noncoding RNA-based strategies to modulate tissue vascularization. J Am Coll Cardiol 66:2005-2015.
Wang CF, Zhao CC, Weng WJ, Lei J, Lin Y, Mao Q, Gao GY, Feng JF, Jiang JY (2017) Regulatory T cells ameliorate tissue plasminogen activator-induced brain haemorrhage after stroke. Brain 140:1914-1931.

Michalk MK, You X, Manavisky Y, Dodaballapur A, Zörnig M, Braun T, John D, Ponomareva Y, Chen W, Uchida S, Boon RA, Dimmeler S (2014) Long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth. Circ Res 114:1389-1397.

Mueller CA, Schluesener HJ, Fauser U, Conrad S, Schwaab JM (2007) Lesional expression of the endogenous angiogenesis inhibitor endostatin/collagen XVIII following traumatic brain injury (TBI). Exp Neurol 208:228-237.

Park E, Bell JD, Siddiq IP, Baker AJ (2009) An analysis of regional microvascular loss and recovery following two grades of fluid percussion trauma: a role for hypoxia-inducible factors in traumatic brain injury. J Cereb Blood Flow Metab 29:575-584.

Pericci du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark AJ, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, et al. (2020) The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. J Physiol 598:3793-3801.

Qu D, Sun WW, Li L, Ma S, Sun J, Xin T, Hou W, Wang JH (2019) Long noncoding RNA MALAT1 releases epigenetic silencing of HIV-1 replication by displacing the polycomb repressive complex 2 from binding to the LTR promoter. Nucleic Acids Res 47:3013-3027.

Ren B, Rose JB, Liu Y, Jaskular-Szul R, Contreras C, Beck A, Chen H (2019) Heterogeneity of vascular endothelial cells, de novo arteriogenesis and therapeutic implications in pancreatic neuroendocrine tumors. J Clin Med 8:1890.

Ren C, Yao Y, Han R, Huang Q, Li H, Wang B, Li S, Li M, Mao Y, Mao X, Xie L, Zhou L, Hu J, Ji X, Ji N (2018) Cerebral ischemia induces angiogenesis in the peri-infarct regions via Notch1 signaling activation. Exp Neurol 304:30-40.

Salehi A, Zhang JH, Obenaus A (2017) Response of the cerebral vasculature following traumatic brain injury. J Cereb Blood Flow Metab 37:2320-2339.

Schmid MC, Avraamides CJ, Foubert P, Shaked Y, Kang SW, Kerbel RS, Varner JA (2011) Combined blockade of integrin-αβ1 + plus cytokines SDF-1a or IL-1β potently inhibits tumor inflammation and growth. Cancer Res 71:6965-6975.

Skold MK, Risling M, Holm S (2006) Inhibition of vascular endothelial growth factor receptor 2 activity in experimental brain contusions aggravates injury outcome and leads to early increased neuronal and glial degeneration. Eur J Neurosci 23:31-34.

Skold MK, von Gertten C, Sandberg-Nordqvist AC, Mathiesen T, Holm S (2005) VEGF and VEGFR receptor expression after experimental brain contusion in rat. J Neurotrauma 22:353-367.

Stein SC, Georgoff P, Meghan S, Mizia K, Sonnad SS (2010) 150 years of treating severe traumatic brain injury: a systematic review of progress in mortality. J Neurotrauma 27:1343-1353.

Sun M, Kraus WL (2015) From discovery to function: the expanding roles of long noncoding RNA. Oncotarget 6:41045-41055.

Yao RW, Wang Y, Chen LL (2019) Cellular functions of long noncoding RNAs. Nat Cell Biol 21:542-551.

Zhang X, Tang X, Hamblin MH, Yin KJ (2018) Long non-coding RNA Malat1 regulates angiogenesis in hindlimb ischemia. J Mol Med 14:632-641.

Zhu Y, Lee C, Shen F, Du R, Young WL, Yang GY (2005) Angiopoietin-2 facilitates brain tumor angiogenesis via downregulation of lncRNA MALAT1 and EZH2 in mouse. Brain Res 106:1247-1266.

Zhu Y, Yu Z, Fu X, Xue Y, Chen H, Zheng J, Zhang H, Liu L, Mei Y, Cao D, Xing Z, Sun X, Cheng C, Li T, Hou W, Wang JH (2019) Long non-coding RNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer. Oncotarget 6:41045-41055.

Wang, G, Jiang X, Pu H, Zhang W, An C, Hu X, Liou AK, leak RK, Gao Y, Chen J (2013) Scriptaid, a novel histone deacetylase inhibitor, protects against traumatic brain injury via modulation of PTEN and AKT pathway: scriptaid protects against TBI via AKT. Neurotherapeutics 10:124-142.

Wang Y, Xie Y, Li L, He Y, Zheng D, Du Y, Yu L, Tang L, Wang Y, Wang Z (2018) EZH2-RIP-Seq identifies tissue-specific long non-coding RNAs. Curr Gene Ther 18:275-285.

Williams CK, Li JL, Murga M, Harris AL, Tosato G (2006) Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107:931-939.

Wright DW, Yeatts SD, Silbergleit R, Palesch YS, Hertzberg VS, Frankel M, Goldstein FC, Caveney AF, Howlett-Smith H, Bengelink EM, Manley GT, Merck LH, Janis LS, Barsan WG, NETT Investigators (2014) Very early administration of progesterone for acute traumatic brain injury. N Engl J Med 371:2457-2466.

Xu K, Wu ZJ, Groner AC, He HH, Cai L, Ris RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montroni R, Magi-Galluzzi C, Kantoff PW, Balk SP, et al. (2012) EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338:1465-1469.

Yang LX, Yang LK, Zhu J, Chen JH, Wang YH, Xiong K (2019) Expression signatures of long non-coding RNA and mRNA in human traumatic brain injury. Neuro Regen Res 14:632-641.

Yao RW, Wang Y, Chen LL (2019) Cellular functions of long noncoding RNAs. Nat Cell Biol 21:542-551.

Zhou C, Chen H, Zheng JF, Guo ZD, Huang ZJ, Wu Y, Zhong JJ, Sun XC, Cheng CJ (2019) IncRNA MALAT1 accelerates skeletal muscle cell apoptosis and inflammatory response in sepsis by decreasing BRL1 expression by recruiting EZH2. Mol Ther Nucleic Acids 21:1120-1121.

Yu Y, Cao F, Ran Q, Wang F (2017a) Long non-coding RNA Gm4149 promotes trauma-induced astrocyte apoptosis by targeting tumor necrosis factor α. Biochem Biophys Res Commun 491:478-485.

Yu Y, Rayile A, Zhang X, Li Y, Zhao Q (2017b) Ulinastatin protects against lipopolysaccharide-induced cardiac microvascular endothelial cell dysfunction via downregulation of IncRNA MALAT1 and EZH2 in sepsis. Int J Mol Med 39:1269-1276.

Zhang X, Tang X, Hamblin MH, Yin KJ (2018) Long non-coding RNA Malat1 regulates angiogenesis in hindlimb ischemia. J Mol Med 14:632-641.

Zhang X, Tang X, Liu K, Hamblin MH, Yin KJ (2017) Long noncoding RNA MALAT1 regulates cerebrovascular pathologies in ischemic stroke. J Neurosci 37:1797-1806.

Zhang Y, Wang J, Zhang Y, Wei J, Wu R, Cai H (2019) Overexpression of long noncoding RNA Malat1 ameliorates traumatic brain injury induced brain edema by inhibiting AQP4 and the NF-κB/p65 pathway. J Cell Biochem 120:17584-17592.

Zhang J, Jiang L, Cheng C, Huang Z, Zhang H, Liu H, He J, Cao F, Peng J, Jiang Y, Sun Y (2016) Altered expression of long non-coding RNA and mRNA in mouse cortex after traumatic brain injury. Brain Res 1648:589-600.

Zhou C, Chen H, Zheng JF, Guo ZD, Huang ZJ, Wu Y, Zhong JJ, Sun XC, Cheng CJ (2020) Pentraxin 3 contributes to neurogenesis after traumatic brain injury in mice. Neuro Regen Res 15:2318-2326.

Zhu Y, Lee C, Chen F, Du R, Young WL, Yang GY (2005) Antiangiogenic-2 facilitates vascular endothelial growth factor-induced angiogenesis in the mature mouse brain. Stroke 36:1533-1537.

C-Editor: Zhao M; S-Editors: Yu J, Li CH; L-Editors: Crawford M, Yu J, Song LP; T-Editor: Jia Y